Latest Patent Grants News

Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

Zeotech Limited has secured a strategic MOU with Holcim Australia to advance its AusPozz™ low-carbon concrete product, alongside promising methane reduction results and a newly granted Japanese patent.

First Graphene has secured key patents for its Kainos Technology in Australia and Korea, positioning itself at the forefront of producing graphite, graphene, and hydrogen from petroleum waste. This milestone aligns with growing global demand for critical minerals essential to the energy transition.

Sparc Technologies has committed to Stage 2 of its hydrogen joint venture, secured a pioneering patent in Morocco, and progressed graphene additive trials, signaling momentum in its clean energy and materials innovation.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.